Valion Bio (VBIO) Free Cash Flow (2021 - 2025)
Valion Bio (VBIO) posted quarterly Free Cash Flow of -$2.3 million for Q4 2025, down 240.91% year-over-year from $1.6 million in Q4 2024, and down 15.67% quarter-over-quarter from -$2.0 million in Q3 2025.
Valion Bio (VBIO) Free Cash Flow (2021 - 2025) Analysis & Trends
Valion Bio's Free Cash Flow history runs 5 years deep, the most recent figure standing at -$2.3 million for Q4 2025.
- In Q4 2025, Free Cash Flow fell 240.91% year-over-year to -$2.3 million; the TTM figure through Dec 2025 stood at -$7.0 million (down 38.43% YoY), while the FY2025 annual figure was -$7.0 million, down 38.49% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$2.3 million, down from -$2.0 million in the prior quarter.
- The five-year high for Free Cash Flow was -$543000.0 in Q2 2021, with the low at -$2.8 million in Q3 2022.
- The 5-year median for Free Cash Flow is -$1.8 million (2023), against an average of -$1.8 million.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow jumped 62.34% in 2024, then plunged 240.91% in 2025.
- Valion Bio's Free Cash Flow stood at -$2.8 million in 2021, then rose by 19.6% to -$2.2 million in 2022, then advanced by 18.39% to -$1.8 million in 2023, then surged by 62.34% to -$682000.0 in 2024, then slumped by 240.91% to -$2.3 million in 2025.
- Business Quant data shows VBIO's Free Cash Flow at -$2.3 million in Q4 2025, -$2.0 million in Q3 2025, and -$1.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 477.44 Mn |
| 10 | Valion Bio | 404,923.65 | -1.80 Mn | -45,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.33 Mn |
| Dec 31, 2025 | -2.33 Mn |
| Sep 30, 2025 | -2.01 Mn |
| Sep 30, 2025 | -2.01 Mn |
| Jun 30, 2025 | -1.80 Mn |
| Jun 30, 2025 | -1.80 Mn |
| Mar 31, 2025 | -900,000.00 |
| Mar 31, 2025 | -900,000.00 |
| Dec 31, 2024 | -682,000.00 |
| Dec 31, 2024 | -682,000.00 |
| Sep 30, 2024 | -1.45 Mn |
| Sep 30, 2024 | -1.45 Mn |
| Jun 30, 2024 | -1.25 Mn |
| Jun 30, 2024 | -1.25 Mn |
| Mar 31, 2024 | -1.70 Mn |
| Mar 31, 2024 | -1.70 Mn |
| Dec 31, 2023 | -1.81 Mn |
| Dec 31, 2023 | -1.81 Mn |
| Sep 30, 2023 | -1.80 Mn |
| Sep 30, 2023 | -1.80 Mn |